[Federal Register Volume 79, Number 148 (Friday, August 1, 2014)]
[Notices]
[Pages 44807-44811]
[FR Doc No: 2014-18113]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-0007]

Prescription Drug User Fee Rates for Fiscal Year 2015

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the rates
for prescription drug user fees for fiscal year (FY) 2015. The Federal
Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the
Prescription Drug User Fee Amendments of 2012 (PDUFA V), authorizes FDA
to collect user fees for certain applications for the review of human
drug and biological products, on establishments where the products are
made, and on such products. This notice establishes the fee rates for
FY 2015.

FOR FURTHER INFORMATION CONTACT: Robert J. Marcarelli, Office of
Financial Management, Food and Drug

Administration, 8455 Colesville Rd., COLE-14202F, Silver Spring, MD
20993-0002,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Background

    Sections 735 and 736 of the FD&C Act (21 U.S.C. 379g and 379h,
respectively), establish three different kinds of user fees. Fees are
assessed on the following: (1) Certain types of applications and
supplements for the review of human drug and biological products; (2)
certain establishments where such products are made; and (3) certain
products (section 736(a) of the FD&C Act). When certain conditions are
met, FDA may waive or reduce fees (section 736(d) of the FD&C Act).
    For FY 2013 through FY 2017, the base revenue amounts for the total
revenues from all PDUFA fees are established by PDUFA V. The base
revenue amount for FY 2013, which became the base amount for the
remaining 4 FYs of PDUFA V, is $718,669,000, as published in the
Federal Register of August 1, 2012 (77 FR 45639). The FY 2013 base
revenue amount is further adjusted each year after FY 2013 for
inflation and workload. Fees for applications, establishments, and
products are to be established each year by FDA so that revenues from
each category will provide one-third of the total revenue to be
collected each year.
    This document provides fee rates for FY 2015 for an application
requiring clinical data ($2,335,200), for an application not requiring
clinical data or a supplement requiring clinical data ($1,167,600), for
an establishment ($569,200), and for a product ($110,370). These fees
are effective on October 1, 2014, and will remain in effect through
September 30, 2015. For applications and supplements that are submitted
on or after October 1, 2014, the new fee schedule must be used.
Invoices for establishment and product fees for FY 2015 will be issued
in August 2014 using the new fee schedule.

II. Fee Revenue Amount for FY 2015

    The base revenue amount for FY 2015 is $718,669,000 prior to
adjustments for inflation and workload (see section 736(c)(1) and
(c)(2) of the FD&C Act).

A. FY 2015 Statutory Fee Revenue Adjustments for Inflation

    PDUFA V specifies that the $718,669,000 is to be further adjusted
for inflation increases for FY 2015 using two separate adjustments--one
for personnel compensation and benefits (PC&B) and one for non-PC&B
costs (see section 736(c)(1) of the FD&C Act).
    The component of the inflation adjustment for payroll costs shall
be 1 plus the average annual percent change in the cost of all PC&B
paid per full-time equivalent (FTE) position at FDA for the first 3 of
the preceding 4 FYs, multiplied by the proportion of PC&B costs to
total FDA costs of process for the review of human drug applications
for the first 3 of the preceding 4 FYs (see section 736(c)(1)(A) and
(c)(1)(B) of the FD&C Act). The total PC&B paid and numbers of FTE
paid, from which the average cost per FTE can be derived, are published
in FDA's Justification of Estimates for Appropriations Committees.
    Table 1 summarizes that actual cost and FTE data for the specified
FYs, and provides the percent changes from the previous FYs and the
average percent changes over the first 3 of the 4 FYs preceding FY
2015. The 3-year average is 1.8829 percent.

              Table 1--FDA Personnel Compensation and Benefits (PC&B) Each Year and Percent Changes
----------------------------------------------------------------------------------------------------------------
               Fiscal year                      2011              2012              2013         3-Year average
----------------------------------------------------------------------------------------------------------------
Total PC&B..............................    $1,761,655,000    $1,824,703,000    $1,927,703,000  ................
Total FTE...............................            13,331            13,382            13,974  ................
PC&B per FTE............................          $132,147          $136,355          $137,949  ................
Percent Change from Previous Year.......           1.2954%           3.1843%           1.1690%           1.8829%
----------------------------------------------------------------------------------------------------------------

    The statute specifies that this 1.8829 percent should be multiplied
by the proportion of PC&B costs to total FDA costs of the process for
the review of human drug applications. Table 2 shows the PC&B and the
total obligations for the process for the review of human drug
applications for 3 FYs.

    Table 2--PC&B as a Percent of Fee Revenues Spent on the Process for the Review of Human Drug Applications
----------------------------------------------------------------------------------------------------------------
               Fiscal year                      2011              2012              2013         3-Year average
----------------------------------------------------------------------------------------------------------------
Total PC&B..............................      $596,627,595     $ 592,642,252      $568,206,210  ................
Total Costs.............................    $1,025,621,707    $1,032,419,218      $966,169,007  ................
PC&B Percent............................          58.1723%          57.4033%          58.8102%          58.1286%
----------------------------------------------------------------------------------------------------------------

    The payroll adjustment is 1.8829 percent from table 1 multiplied by
58.1286 percent (or 1.0945 percent).
    The statute specifies that the portion of the inflation adjustment
for non-payroll costs is the average annual percent change that
occurred in the Consumer Price Index (CPI) for urban consumers
(Washington-Baltimore, DC-MD-VA-WV; not seasonally adjusted; all items;
annual index) for the first 3 years of the preceding 4 years of
available data multiplied by the proportion of all costs other than
PC&B costs to total costs of the process for the review of human drug
applications for the first 3 years of the preceding 4 fiscal years (see
section 736(c)(1)(C) of the FD&C Act). Table 3 provides the summary
data for the percent changes in the specified CPI for the Washington-
Baltimore area. The data is published by the Bureau of Labor Statistics
and can be found on their Web site at http://data.bls.gov/cgi-bin/surveymost?cu by checking the box marked ``Washington-Baltimore All
Items, November 1996=100-CUURA311SA0'' and then clicking on the
``Retrieve Data'' button.

             Table 3--Annual and 3-Year Average Percent Change in CPI for Washington-Baltimore Area
----------------------------------------------------------------------------------------------------------------
                  Year                          2011              2012              2013         3-Year average
----------------------------------------------------------------------------------------------------------------
Annual CPI..............................           146.975           150.212           152.500  ................
Annual Percent Change...................           3.3449%           2.2024%           1.5232%           2.3568%
----------------------------------------------------------------------------------------------------------------

    To calculate the inflation adjustment for non-payroll costs, we
multiply the 2.3568 percent by the proportion of all costs other than
PC&B to total costs of the process for the review of human drug
applications obligated. Since 58.1286 percent was obligated for PC&B as
shown in table 2, 41.8714 percent is the portion of costs other than
PC&B (100 percent minus 58.1286 percent equals 41.8714 percent). The
non-payroll adjustment is 2.3568 percent times 41.8714 percent, or
0.9868 percent.
    Next, we add the payroll adjustment (1.0945 percent) to the non-
payroll adjustment (0.9868 percent), for a total inflation adjustment
of 2.0813 percent (rounded) for FY 2015.
    PDUFA V provides for this inflation adjustment to be compounded
after FY 2013 (see section 736(c)(1) of the FD&C Act). This factor for
FY 2015 (2.0813 percent) is compounded by adding 1 and then multiplying
by 1 plus the inflation adjustment factor for FY 2014 (2.20 percent),
as published in the Federal Register of August 2, 2013 (78 FR 46980 at
46982), which equals to 1.043271 (rounded) (1.020813 times 1.0220) for
FY 2015. We then multiply the base revenue amount for FY 2015
($718,669,000) by 1.043271, yielding an inflation-adjusted amount of
$749,766,526.

B. FY 2015 Statutory Fee Revenue Adjustments for Workload

    The statute specifies that after the $718,669,000 has been adjusted
for inflation, the inflation-adjusted amount shall be further adjusted
for workload (see section 736(c)(2) of the FD&C Act).
    To calculate the FY 2015 workload adjustment, FDA calculated the
average number of each of the four types of applications specified in
the workload adjustment provision: (1) Human drug applications; (2)
active commercial investigational new drug applications (INDs)
(applications that have at least one submission during the previous 12
months); (3) efficacy supplements; and (4) manufacturing supplements
received over the 3-year period that ended on June 30, 2012 (base
years), and the average number of each of these types of applications
over the most recent 3 year period that ended June 30, 2014.
    The calculations are summarized in table 4. The 3-year averages for
each application category are provided in column 1 (``3-Year Average
Base Years 2010-2012'') and column 2 (``3-Year Average 2012-2014'').
Column 3 reflects the percent change in workload from column 1 to
column 2. Column 4 shows the weighting factor for each type of
application, estimating how much of the total FDA drug review workload
was accounted for by each type of application in the table during the
most recent 3 years. Column 5 is the weighted percent change in each
category of workload. This was derived by multiplying the weighting
factor in each line in column 4 by the percent change from the base
years in column 3. The sum of the values in column 5 is added,
reflecting an increase in workload of 7.49 percent (rounded) for FY
2015 when compared to the base years.

                               Table 4--Workload Adjuster Calculation for FY 2015
----------------------------------------------------------------------------------------------------------------
                                  3-Year average                  Percent change     Weighting
                                    base years    3-Year average   (column 1 to       factor         Weighted
                                     2010-2012       2012-2014       column 2)       (percent)    percent change
Application type                        Column 1        Column 2        Column 3        Column 4        Column 5
----------------------------------------------------------------------------------------------------------------
New Drug Applications/Biologics            124.3           141.3         13.6766            37.3            5.10
 License Applications...........
Active Commercial INDs..........          6830.0          7141.3          4.5578            41.4            1.89
Efficacy Supplements............           136.3           156.7         14.9670             7.5            1.12
Manufacturing Supplements.......          2548.3          2433.7         -4.4971            13.8           -0.62
                                 -------------------------------------------------------------------------------
FY 2015 Workload Adjuster.......  ..............  ..............  ..............  ..............            7.49
----------------------------------------------------------------------------------------------------------------

    Table 5 shows the calculation of the revenue amount for FY 2015.
The $718,669,000 subject to adjustment on the first line is multiplied
by the inflation adjustment factor of 1.043271, resulting in the
inflation-adjusted amount on the third line, $749,766,526. That amount
is then multiplied by one plus the workload adjustment of 7.49 percent,
resulting in the inflation and workload adjusted amount of $805,924,000
on the fifth line, rounded to the nearest thousand dollars.

     Table 5--PDUFA Revenue Amount for FY 2015, Summary Calculation
------------------------------------------------------------------------

------------------------------------------------------------------------
FY 2013 Revenue Amount and Base         $718,669,000  Line 1.
 Subsequent FYs as published in the
 Federal Register of August 1, 2012
 (77 FR 45639) (Rounded to nearest
 thousand dollars).
Inflation Adjustment Factor for FY          1.043271  Line 2.
 2015 (1 plus 4.3271 percent).
Inflation Adjusted Amount...........    $749,766,526  Line 3.
Workload Adjustment Factor for FY             1.0749  Line 4.
 2015 (1 plus 7.49 percent).
Inflation and Workload Adjusted         $805,924,000  Line 5.
 Amount (Rounded to nearest thousand
 dollars).
------------------------------------------------------------------------

    PDUFA specifies that one-third of the total fee revenue is to be
derived from application fees, one-third from establishment fees, and
one-third from product fees (see section 736(b)(2) of the FD&C Act).
Accordingly, one-third of the total revenue amount ($805,924,000), or a
total of $268,641,333, is the amount of fee revenue that will be
derived from each of these fee categories: Application Fees,
Establishment Fees, and Product Fees.

III. Application Fee Calculations

A. Application Fee Revenues and Application Fees

    Application fees will be set to generate one-third of the total fee
revenue amount, or $268,641,333 in FY 2015.

B. Estimate of the Number of Fee-Paying Applications and Setting the
Application Fees

    For FY 2013 through FY 2017, FDA will estimate the total number of
fee-paying full application equivalents (FAEs) it expects to receive
the next FY by averaging the number of fee-paying FAEs received in the
3 most recently completed FYs.
    In estimating the number of fee-paying FAEs, a full application
requiring clinical data counts as one FAE. An application not requiring
clinical data counts as one-half an FAE, as does a supplement requiring
clinical data. An application that is withdrawn, or refused for filing,
counts as one-fourth of an FAE if the applicant initially paid a full
application fee, or one-eighth of an FAE if the applicant initially
paid one-half of the full application fee amount.
    As table 6 shows, the average number of fee-paying FAEs received
annually in the most recent 3-year period is 115.042 FAEs. FDA will set
fees for FY 2015 based on this estimate as the number of full
application equivalents that will pay fees.

                                     Table 6--Fee-Paying FAE 3-Year Average
----------------------------------------------------------------------------------------------------------------
                 FY                          2011               2012               2013          3-Year average
----------------------------------------------------------------------------------------------------------------
Fee-Paying FAEs.....................           108.250            122.375            114.500            115.042
----------------------------------------------------------------------------------------------------------------

    The FY 2015 application fee is estimated by dividing the average
number of full applications that paid fees over the latest 3 years,
115.042, into the fee revenue amount to be derived from application
fees in FY 2015, $268,641,333. The result, rounded to the nearest
hundred dollars, is a fee of $2,335,200 per full application requiring
clinical data, and $1,167,600 per application not requiring clinical
data or per supplement requiring clinical data.

IV. Fee Calculations for Establishment and Product Fees

A. Establishment Fees

    At the beginning of FY 2014, the establishment fee was based on an
estimate that 455 establishments would be subject to and would pay
fees. By the end of FY 2014, FDA estimates that 509 establishments will
have been billed for establishment fees, before all decisions on
requests for waivers or reductions are made. FDA estimates that a total
of 20 establishment fee waivers or reductions will be made for FY 2014.
In addition, FDA estimates that another 17 full establishment fees will
be exempted this year based on the orphan drug exemption in section
736(k) of the FD&C Act. Subtracting 37 establishments (20 waivers, plus
the estimated 17 establishments under the orphan exemption) from 509
leaves a net of 472 fee-paying establishments. FDA will use 472 to
estimate the FY 2015 establishments paying fees. The fee per
establishment is determined by dividing the adjusted total fee revenue
to be derived from establishments ($268,641,333) by the estimated 472
establishments, for an establishment fee rate for FY 2015 of $569,200
(rounded to the nearest hundred dollars).

B. Product Fees

    At the beginning of FY 2014, the product fee was based on an
estimate that 2,425 products would be subject to and would pay product
fees. By the end of FY 2014, FDA estimates that 2,545 products will
have been billed for product fees, before all decisions on requests for
waivers, reductions, or exemptions are made. FDA assumes that there
will be 69 waivers and reductions granted. In addition, FDA estimates
that another 42 product fees will be exempted this year based on the
orphan drug exemption in section 736(k) of the FD&C Act. FDA estimates
that 2,434 products will qualify for product fees in FY 2014, after
allowing for an estimated 111 waivers and reductions, including the
orphan drug products, and will use this number for its FY 2015
estimate. The FY 2015 product fee rate is determined by dividing the
adjusted total fee revenue to be derived from product fees
($268,641,333) by the estimated 2,434 products for a FY 2015 product
fee of $110,370 (rounded to the nearest ten dollars).

V. Fee Schedule for FY 2015

    The fee rates for FY 2015 are set out in table 7:

                    Table 7--Fee Schedule for FY 2015
------------------------------------------------------------------------
                                                           Fee rates for
                      Fee category                            FY 2015
------------------------------------------------------------------------
Applications:
  Requiring clinical data...............................      $2,335,200
  Not requiring clinical data...........................       1,167,600
  Supplements requiring clinical data...................       1,167,600
Establishments..........................................         569,200
Products................................................         110,370
------------------------------------------------------------------------

VI. Fee Payment Options and Procedures

A. Application Fees

    The appropriate application fee established in the new fee schedule
must be paid for any application or supplement subject to fees under
PDUFA that is received on or after October 1, 2014. Payment must be
made in U.S. currency by check, bank draft, or U.S. postal money order
payable to the order of the Food and Drug Administration. Please
include the user fee identification (ID) number on your check, bank
draft, or postal money order. Your payment can be mailed to: Food and
Drug Administration, P.O. Box 979107, St. Louis, MO 63197-9000.
    If checks are to be sent by a courier that requests a street
address, the courier can deliver the checks to: U.S. Bank, Attention:
Government Lockbox 979107, 1005 Convention Plaza, St. Louis, MO 63101.
(Note: This U.S. Bank address is for courier delivery only. Contact the
U.S. Bank at<PHONE_NUMBER> if you have any questions concerning courier
delivery.)

    Please make sure that the FDA post office box number (P.O. Box
979107) is written on the check, bank draft, or postal money order.
    Wire transfer payment may also be used. Please reference your
unique user fee ID number when completing your transfer. The
originating financial institution may charge a wire transfer fee.
Please ask your financial institution about the fee and add it to your
payment to ensure that your fee is fully paid. The account information
for wire transfers is as follows: New York Federal Reserve Bank, U.S.
Department of the Treasury, TREAS NYC, 33 Liberty St., New York, NY
10045, Acct. No.: 75060099, Routing No.: 021030004, SWIFT: FRNYUS33,
Beneficiary: FDA, 8455 Colesville Rd., 14th Floor, Silver Spring, MD
20993-0002.
    Application fees can also be paid online with an electronic check
(ACH). FDA has partnered with the U.S. Department of the Treasury to
use Pay.gov, a Web-based payment application, for online electronic
payment. The Pay.gov feature is available on the FDA Web site after the
user fee ID number is generated.
    The tax identification number of FDA is 53-0196965.

B. Establishment and Product Fees

    FDA will issue invoices for establishment and product fees for FY
2015 under the new fee schedule in August 2014. Payment will be due on
October 1, 2014. FDA will issue invoices in November 2015 for any
products and establishments subject to fees for FY 2015 that qualify
for fee assessments after the August 2014 billing.

    Dated: July 25, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-18113 Filed 7-31-14; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register Volume 88, Number 207 (Friday, October 27, 2023)]
[Notices]
[Pages 73836-73837]
[FR Doc No: 2023-23798]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP24-5-000]

Columbia Gas Transmission, LLC; Notice of Request Under Blanket
Authorization and Establishing Intervention and Protest Deadline

    Take notice that on October 13, 2023, Columbia Gas Transmission
(Columbia), 700 Louisiana Street, Suite 1300, Houston, Texas 77002-
2700, filed in the above referenced docket, a prior notice request
pursuant to sections 157.208 and 157.216 of the Commission's
regulations under the Natural Gas Act (NGA), and Columbia's blanket
certificate issued in Docket No. CP83-76-000, for authorization to
abandon and replace sections of its existing SR538 pipeline, abandon
its existing SR424 pipeline, install a bi-directional launching and
receiving station for in-line inspection devices, and perform other
related appurtenant activities. All of the above facilities are located
in Hocking County, Ohio (SR538 Pipeline Replacement Project). The
project will allow Columbia to conduct in-line inspection, or pigging,
of Line SR538 to ensure compliance with DOT requirements for
inspections of pipeline systems. The estimated cost for the project is
$24.7 million, all as more fully set forth in the request which is on
file with the Commission and open to public inspection.
    In addition to publishing the full text of this document in the
Federal Register, the Commission provides all interested persons an
opportunity to view and/or print the contents of this document via the
internet through the Commission's Home Page (www.ferc.gov) using the
``eLibrary'' link. Enter the docket number excluding the last three
digits in the docket number field to access the document. At this time,
the Commission has suspended access to the Commission's Public
Reference Room. For assistance, contact the Federal Energy Regulatory
Commission at [email protected] or call toll-free, (886) 208-
3676 or TTY<PHONE_NUMBER>.
    Any questions concerning this request should be directed to David
A. Alonzo, 700 Louisiana Street, Suite 1300, Houston, Texas 77002-2700
at<PHONE_NUMBER> or email at [email protected].

Public Participation

    There are three ways to become involved in the Commission's review
of this project: you can file a protest to the project, you can file a
motion to intervene in the proceeding, and you can file comments on the
project. There is no fee or cost for filing protests, motions to
intervene, or comments. The deadline for filing protests, motions to
intervene, and comments is 5 p.m. Eastern Time on December 22, 2023.
How to file protests, motions to intervene, and comments is explained
below.
    The Commission's Office of Public Participation (OPP) supports
meaningful public engagement and participation in Commission
proceedings. OPP can help members of the public, including landowners,
environmental justice communities, Tribal members and others, access
publicly available information and navigate Commission processes. For
public inquiries and assistance with making filings such as
interventions, comments, or requests for

rehearing, the public is encouraged to contact OPP at<PHONE_NUMBER> or
[email protected].

Protests

    Pursuant to section 157.205 of the Commission's regulations under
the NGA,\1\ any person \2\ or the Commission's staff may file a protest
to the request. If no protest is filed within the time allowed or if a
protest is filed and then withdrawn within 30 days after the allowed
time for filing a protest, the proposed activity shall be deemed to be
authorized effective the day after the time allowed for protest. If a
protest is filed and not withdrawn within 30 days after the time
allowed for filing a protest, the instant request for authorization
will be considered by the Commission.
---------------------------------------------------------------------------

    \1\ 18 CFR 157.205.
    \2\ Persons include individuals, organizations, businesses,
municipalities, and other entities. 18 CFR 385.102(d).
---------------------------------------------------------------------------

    Protests must comply with the requirements specified in section
157.205(e) of the Commission's regulations,\3\ and must be submitted by
the protest deadline, which is December 22, 2023. A protest may also
serve as a motion to intervene so long as the protestor states it also
seeks to be an intervenor.
---------------------------------------------------------------------------

    \3\ 18 CFR 157.205(e).
---------------------------------------------------------------------------

Interventions

    Any person has the option to file a motion to intervene in this
proceeding. Only intervenors have the right to request rehearing of
Commission orders issued in this proceeding and to subsequently
challenge the Commission's orders in the U.S. Circuit Courts of Appeal.
    To intervene, you must submit a motion to intervene to the
Commission in accordance with Rule 214 of the Commission's Rules of
Practice and Procedure \4\ and the regulations under the NGA \5\ by the
intervention deadline for the project, which is December 22, 2023. As
described further in Rule 214, your motion to intervene must state, to
the extent known, your position regarding the proceeding, as well as
your interest in the proceeding. For an individual, this could include
your status as a landowner, ratepayer, resident of an impacted
community, or recreationist. You do not need to have property directly
impacted by the project in order to intervene. For more information
about motions to intervene, refer to the FERC website at https://www.ferc.gov/resources/guides/how-to/intervene.asp.
---------------------------------------------------------------------------

    \4\ 18 CFR 385.214.
    \5\ 18 CFR 157.10.
---------------------------------------------------------------------------

    All timely, unopposed motions to intervene are automatically
granted by operation of Rule 214(c)(1). Motions to intervene that are
filed after the intervention deadline are untimely and may be denied.
Any late-filed motion to intervene must show good cause for being late
and must explain why the time limitation should be waived and provide
justification by reference to factors set forth in Rule 214(d) of the
Commission's Rules and Regulations. A person obtaining party status
will be placed on the service list maintained by the Secretary of the
Commission and will receive copies (paper or electronic) of all
documents filed by the applicant and by all other parties.

Comments

    Any person wishing to comment on the project may do so. The
Commission considers all comments received about the project in
determining the appropriate action to be taken. To ensure that your
comments are timely and properly recorded, please submit your comments
on or before December 22, 2023. The filing of a comment alone will not
serve to make the filer a party to the proceeding. To become a party,
you must intervene in the proceeding.

How To File Protests, Interventions, and Comments

    There are two ways to submit protests, motions to intervene, and
comments. In both instances, please reference the Project docket number
CP24-5-000 in your submission.
    (1) You may file your protest, motion to intervene, and comments by
using the Commission's eFiling feature, which is located on the
Commission's website (www.ferc.gov) under the link to Documents and
Filings. New eFiling users must first create an account by clicking on
``eRegister.'' You will be asked to select the type of filing you are
making; first select ``General'' and then select ``Protest'',
``Intervention'', or ``Comment on a Filing''; or \6\
---------------------------------------------------------------------------

    \6\ Additionally, you may file your comments electronically by
using the eComment feature, which is located on the Commission's
website at www.ferc.gov under the link to Documents and Filings.
Using eComment is an easy method for interested persons to submit
brief, text-only comments on a project.
---------------------------------------------------------------------------

    (2) You can file a paper copy of your submission by mailing it to
the address below. Your submission must reference the Project docket
number CP24-5-000.
    To file via USPS: Kimberly D. Bose, Secretary, Federal Energy
Regulatory Commission, 888 First Street NE, Washington, DC 20426.
    To file via any other method: Kimberly D. Bose, Secretary, Federal
Energy Regulatory Commission, 12225 Wilkins Avenue, Rockville, Maryland
20852.
    The Commission encourages electronic filing of submissions (option
1 above) and has eFiling staff available to assist you at (202) 502-
8258 or [email protected].
    Protests and motions to intervene must be served on the applicant
either by mail or email (with a link to the document) at: David A.
Alonzo, Manager, Project Authorizations, 700 Louisiana Street, Suite
1300, Houston, Texas 77002-2700 at<PHONE_NUMBER>, or at
[email protected]. Any subsequent submissions by an intervenor
must be served on the applicant and all other parties to the
proceeding. Contact information for parties can be downloaded from the
service list at the eService link on FERC Online.

Tracking the Proceeding

    Throughout the proceeding, additional information about the project
will be available from the Commission's Office of External Affairs, at
(866) 208-FERC, or on the FERC website at www.ferc.gov using the
``eLibrary'' link as described above. The eLibrary link also provides
access to the texts of all formal documents issued by the Commission,
such as orders, notices, and rulemakings.
    In addition, the Commission offers a free service called
eSubscription which allows you to keep track of all formal issuances
and submittals in specific dockets. This can reduce the amount of time
you spend researching proceedings by automatically providing you with
notification of these filings, document summaries, and direct links to
the documents. For more information and to register, go to
www.ferc.gov/docs-filing/esubscription.asp.

    Dated: October 23, 2023.
Kimberly D. Bose,
Secretary.
[FR Doc. 2023-23798 Filed 10-26-23; 8:45 am]
BILLING CODE 6717-01-P